An Antimitotic and Antivascular Agent BPR0L075 Overcomes Multidrug Resistance and Induces Mitotic Catastrophe in Paclitaxel-Resistant Ovarian Cancer Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wang, Xiaolei ^a   Wu, Erxi ^b   Wu, Jun ^c   Wang, Tian Li ^d   Hsieh, Hsing Pang ^e   Liu, Xinli ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 3 (3',4',5' TRIMETHOXY BENZOYL) 1H INDOLE; ANTIMITOTIC AGENT; BETA TUBULIN; BETA3 TUBULIN; BINDING PROTEIN; BUB1 RELATED PROTEIN; CASPASE 3; CYCLIN B1; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL XL; PROTEIN MPM 2; SURVIVIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; 6-METHOXY-3-(3',4',5'-TRIMETHOXYBENZOYL)-1H-INDOLE; BCL2L1 PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; BUB1 PROTEIN, HUMAN; CYTOTOXIN; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; INDOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL X; PROTEIN SERINE THREONINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; MITOSIS INHIBITION; MULTIDRUG RESISTANCE; OVARY CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION; DNA FRAGMENTATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOSIS; OVARY; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIMITOTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CYCLIN B1; CYTOTOXINS; DNA FRAGMENTATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; MITOSIS; OVARY; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84878807582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065686     Document Type: Article

References (72)

1. Ozols RF, (2006) Challenges for chemotherapy in ovarian cancer. Ann Oncol 17Suppl 5: v181-187.
2. Clarke-Pearson DL, (2009) Clinical practice. Screening for ovarian cancer. N Engl J Med 361: 170-177.
3. Cannistra SA, (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529.
4. Jordan MA, Wilson L, (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265.
5. Rowinsky EK, Donehower RC, (1995) Paclitaxel (taxol). N Engl J Med 332: 1004-1014.
6. Kavallaris M, (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204.
7. Gottesman MM, Fojo T, Bates SE, (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
8. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB, (2003) Mechanisms of Taxol resistance related to microtubules. Oncogene 22: 7280-7295.
9. Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, et al. (2003) Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 42: 5349-5357.
10. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, et al. (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 97: 2904-2909.
11. Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F, (1999) A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem 274: 23875-23882.
12. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, et al. (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17: 1786-1793.
13. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, et al. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293.
14. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, et al. (2005) Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11: 298-305.
15. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL, (2000) Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 275: 17358-17363.
16. Yu D, Liu B, Jing T, Sun D, Price JE, et al. (1998) Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16: 2087-2094.
17. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, et al. (1998) Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 13: 839-848.
18. Panvichian R, Orth K, Day ML, Day KC, Pilat MJ, et al. (1998) Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 58: 4667-4672.
19. Zhou J, O'Brate A, Zelnak A, Giannakakou P, (2004) Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res 64: 8708-8714.
20. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, et al. (2004) BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 64: 4621-4628.
21. Chen CP, Hu CB, Yeh KC, Song JS, Yeh TK, et al. (2010) Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Res 30: 2813-2822.
22. Liu L, Beck H, Wang X, Hsieh HP, Mason RP, et al. (2012) Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts. PLoS One 7: e43314.
23. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH, (1999) The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59: 4237-4241.
24. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, et al. (1999) Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91: 429-433.
25. Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, de Jong MC, et al. (2000) Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 60: 2589-2593.
26. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, et al. (2005) Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 16Suppl 4: iv14-19.
27. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, et al. (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125.
28. Kanakkanthara A, Wilmes A, O'Brate A, Escuin D, Chan A, et al. (2011) Peloruside- and laulimalide-resistant human ovarian carcinoma cells have betaI-tubulin mutations and altered expression of betaII- and betaIII-tubulin isotypes. Mol Cancer Ther 10: 1419-1429.
29. Belotti D, Rieppi M, Nicoletti MI, Casazza AM, Fojo T, et al. (1996) Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin Cancer Res 2: 1725-1730.
30. Wang Y, O'Brate A, Zhou W, Giannakakou P, (2005) Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 4: 1847-1853.
31. Demarcq C, Bunch RT, Creswell D, Eastman A, (1994) The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 5: 983-993.
32. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, et al. (2012) Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 19: 107-120.
33. Friedrich TD, Okubo E, Laffin J, Lehman JM, (1998) Okadaic acid induces appearance of the mitotic epitope MPM-2 in SV40-infected CV-1 cells with a >G2-phase DNA content. Cytometry 31: 260-264.
34. Davis FM, Tsao TY, Fowler SK, Rao PN, (1983) Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci U S A 80: 2926-2930.
35. Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T, (1998) Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 58: 3331-3338.
36. Ogretmen B, Safa AR, (1996) Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer 67: 608-614.
37. Liu JR, Fletcher B, Page C, Hu C, Nunez G, et al. (1998) Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 70: 398-403.
38. Mansilla S, Priebe W, Portugal J, (2006) Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 5: 53-60.
39. Dumontet C, Jordan MA, (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9: 790-803.
40. Schiff PB, Fant J, Horwitz SB, (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667.
41. Arceci RJ, (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81: 2215-2222.
42. Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, et al. (2009) Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer 8: 43.
43. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, et al. (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825-2837.
44. Vakifahmetoglu H, Olsson M, Zhivotovsky B, (2008) Death through a tragedy: mitotic catastrophe. Cell Death Differ 15: 1153-1162.
45. Singh R, George J, Shukla Y, (2010) Role of senescence and mitotic catastrophe in cancer therapy. Cell Div 5: 4.
46. Ianzini F, Mackey MA, (1998) Delayed DNA damage associated with mitotic catastrophe following X-irradiation of HeLa S3 cells. Mutagenesis 13: 337-344.
47. Ianzini F, Mackey MA, (1997) Spontaneous premature chromosome condensation and mitotic catastrophe following irradiation of HeLa S3 cells. Int J Radiat Biol 72: 409-421.
48. Lock RB, Stribinskiene L, (1996) Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 56: 4006-4012.
49. Cenciarelli C, Tanzarella C, Vitale I, Pisano C, Crateri P, et al. (2008) The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis 13: 659-669.
50. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, et al. (2002) Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 8: 2735-2741.
51. Fu Y, Ye D, Chen H, Lu W, Ye F, et al. (2007) Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Gynecol Oncol 105: 66-73.
52. Sudo T, Nitta M, Saya H, Ueno NT, (2004) Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502-2508.
53. Stauber RH, Mann W, Knauer SK, (2007) Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67: 5999-6002.
54. Knauer SK, Mann W, Stauber RH, (2007) Survivin's dual role: an export's view. Cell Cycle 6: 518-521.
55. Mita AC, Mita MM, Nawrocki ST, Giles FJ, (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005.
56. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, et al. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584.
57. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP, (2003) Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116: 2987-2998.
58. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, et al. (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22: 2934-2947.
59. Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, et al. (2011) Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer 18: 657-668.
60. Zhang R, Ma L, Zheng M, Ren J, Wang T, et al. (2010) Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice. Cancer Gene Ther 17: 275-288.
61. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, et al. (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63: 7724-7732.
62. Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S, et al. (2001) Survivin inhibition induces human neural tumor cell death through caspase-independent and-dependent pathways. J Neurochem 79: 426-436.
63. Roninson IB, Broude EV, Chang BD, (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4: 303-313.
64. Okada H, Mak TW, (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4: 592-603.
65. Nakahata K, Miyakoda M, Suzuki K, Kodama S, Watanabe M, (2002) Heat shock induces centrosomal dysfunction, and causes non-apoptotic mitotic catastrophe in human tumour cells. Int J Hyperthermia 18: 332-343.
66. Broker LE, Kruyt FA, Giaccone G, (2005) Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162.
67. Tseng HH, Chuah QY, Yang PM, Chen CT, Chao JC, et al. (2012) Securin enhances the anti-cancer effects of 6-methoxy-3-(3′,4′,5′-trimethoxy-benzoyl)-1H-indole (BPR0L075) in human colorectal cancer cells. PLoS One 7: e36006.
68. Vitale I, Antoccia A, Cenciarelli C, Crateri P, Meschini S, et al. (2007) Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis 12: 155-166.
69. Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S, et al. (2008) DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 15: 555-566.
70. Liou JP, Chang CW, Song JS, Yang YN, Yeh CF, et al. (2002) Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J Med Chem 45: 2556-2562.
71. Jinawath N, Vasoontara C, Yap KL, Thiaville MM, Nakayama K, et al. (2009) NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene 28: 1941-1948.
72. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, et al. (1992) Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 52: 6175-6181.